Emerging treatments
Cannabidiol
Cannabidiol oral solution has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of seizures associated with Lennox-Gastaut's syndrome or Dravet's syndrome in both children and adults. Multi-centre, randomised, placebo-controlled trials are required to investigate efficacy in other patients with severe, treatment-resistant epilepsy.[70][71][72]
Use of this content is subject to our disclaimer